KEZAR LIFE SCIENCES, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.78 USD | +1.00% |
|
-5.64% | -18.63% |
Presenter SpeechRyuk Byun;Morgan Stanley, Research Division;Executive Director (Analysts)Thank...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's lead product candidate, zetomipzomib, is a first-in-class selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib/IIa clinical trial in patients with systemic lupus erythematosus (SLE), with or without lupus nephritis (LN). Its oncology product candidate, KZR-261, is a small molecule agent, targeting the Sec61 translocon and protein secretion pathway, being studied in an open-label Phase I clinical trial designed to evaluate safety and tolerability, pharmacokinetics and pharmacodynamics, as well to explore preliminary anti-tumor activity. This study is being conducted in two parts: dose escalation in patients with locally advanced or metastatic solid malignancies, and dose expansion in patients with selected tumor types.
Calendar
2024-06-18
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
0.7723
USD
Average target price
11.67
USD
Spread / Average Target
+1,410.64%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.63% | 56.22M | |
| +7.72% | 113B | |
| +10.94% | 106B | |
| +0.41% | 22.27B | |
| -11.91% | 22.22B | |
| -5.99% | 19.43B | |
| -37.36% | 17.87B | |
| -5.57% | 17.24B | |
| +6.72% | 14.29B | |
| +35.67% | 12.52B |
- Stock Market
- Equities
- KZR Stock
- News Kezar Life Sciences, Inc.
- Transcript : Kezar Life Sciences, Inc. Presents at Morgan Stanley 20th Annual Global Healthcare Conference, Sep-14-2022 09